Stockreport

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis [Yahoo! Finance]

Alumis Inc.  (ALMS) 
PDF SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies [Read more]